The Grizzly, November 16, 2006

Election Results Bring Significant Changes • Ursinus Maintains its Health • Peace Vigil on Campus • Lecture Examines the Ethical Treatment of Abandoned Embryos • SquadZilla Brings Hip-Hop to Life at Ursinus • Ursinus Campaign Surpasses Goal • HPV and Cervical Cancer: The Facts, Part II • Preview of the Upcoming UCDC Performance • The Labyrinth: Not Just David Bowie in Spandex • Review of The Sisters Rosensweig • Opinions: Nerf: Yardstick of the Pentagon; American Press Needs Revamping • Bears Down Dickinson in Battle of Top Teams in Centennial Conference • Bears Win Third Straight CC Championship!https://digitalcommons.ursinus.edu/grizzlynews/1725/thumbnail.jp

Upregulation of Endothelin-1 May Predict Chemotherapy-Induced Cardiotoxicity in Women with Breast Cancer

As survival in breast cancer patients from newer therapies increases, concerns for chemotherapy-induced cardiotoxicity (CIC) have offset some of these benefits, manifesting as a decline in left ventricular ejection fraction (LVEF). Patients receiving anthracycline-based chemotherapy followed by trastuzumab are at risk for CIC. Previous research evaluating whether clinical biomarkers predict cardiotoxicity has been inconsistent. Recently, angiotensin II type 1 receptor (ATR1) and endothelin 1 (ET1) have been shown to play a role in breast tumor growth. We evaluated ATR1 and ET1 expression in breast cancer tissue and its association with CIC. A total of 33 paraffin-embedded breast tissue specimens from women with breast cancer treated with anthracycline-based chemotherapy and trastuzumab were analyzed by immunohistochemistry (IHC) and qRT-PCR. We found that ET1 expression was increased in patients with an LVEF ≤ 50% (p = 0.032) with a lower LVEF correlating with higher ET1 expression (r = 0.377, p = 0.031). In patients with a change in LVEF of greater than 10%, greater ET1 expression was noted compared to those without a change in LVEF (p = 0.017). Increased ET1 expression in breast tumor tissue is associated with reduced LVEF. Future studies need to examine whether ET1 may be a tissue biomarker that helps predict the risk of developing CIC in women with breast cancer